Suppr超能文献

对链转移抑制剂耐药的HIV-1整合酶变体的生化分析。

Biochemical analysis of HIV-1 integrase variants resistant to strand transfer inhibitors.

作者信息

Dicker Ira B, Terry Brian, Lin Zeyu, Li Zhufang, Bollini Sagarika, Samanta Himadri K, Gali Volodymyr, Walker Michael A, Krystal Mark R

机构信息

Department of Virology, Bristol-Myers Squibb Research and Development, Wallingford, CT 06492, USA.

出版信息

J Biol Chem. 2008 Aug 29;283(35):23599-609. doi: 10.1074/jbc.M804213200. Epub 2008 Jun 24.

Abstract

In this study, eight different HIV-1 integrase proteins containing mutations observed in strand transfer inhibitor-resistant viruses were expressed, purified, and used for detailed enzymatic analyses. All the variants examined were impaired for strand transfer activity compared with the wild type enzyme, with relative catalytic efficiencies (k(p)/K(m)) ranging from 0.6 to 50% of wild type. The origin of the reduced strand transfer efficiencies of the variant enzymes was predominantly because of poorer catalytic turnover (k(p)) values. However, smaller second-order effects were caused by up to 4-fold increases in K(m) values for target DNA utilization in some of the variants. All the variants were less efficient than the wild type enzyme in assembling on the viral long terminal repeat, as each variant required more protein than wild type to attain maximal activity. In addition, the variant integrases displayed up to 8-fold reductions in their catalytic efficiencies for 3'-processing. The Q148R variant was the most defective enzyme. The molecular basis for resistance of these enzymes was shown to be due to lower affinity binding of the strand transfer inhibitor to the integrase complex, a consequence of faster dissociation rates. In the case of the Q148R variant, the origin of reduced compound affinity lies in alterations to the active site that reduce the binding of a catalytically essential magnesium ion. Finally, except for T66I, variant viruses harboring the resistance-inducing substitutions were defective for viral integration.

摘要

在本研究中,表达、纯化了在链转移抑制剂抗性病毒中观察到的含有突变的8种不同HIV-1整合酶蛋白,并用于详细的酶学分析。与野生型酶相比,所有检测的变体的链转移活性均受损,相对催化效率(k(p)/K(m))为野生型的0.6%至50%。变体酶链转移效率降低的主要原因是催化周转(k(p))值较差。然而,一些变体中靶DNA利用的K(m)值增加高达4倍,从而产生了较小的二级效应。在病毒长末端重复序列上组装时,所有变体的效率均低于野生型酶,因为每个变体达到最大活性所需的蛋白量都比野生型多。此外,变体整合酶在3'-加工中的催化效率降低了8倍。Q148R变体是缺陷最严重的酶。这些酶的抗性分子基础被证明是由于链转移抑制剂与整合酶复合物的亲和力较低,这是解离速率加快的结果。就Q148R变体而言,化合物亲和力降低的原因在于活性位点的改变,从而减少了催化必需镁离子的结合。最后,除T66I外,携带抗性诱导替代的变体病毒在病毒整合方面存在缺陷。

相似文献

1
Biochemical analysis of HIV-1 integrase variants resistant to strand transfer inhibitors.
J Biol Chem. 2008 Aug 29;283(35):23599-609. doi: 10.1074/jbc.M804213200. Epub 2008 Jun 24.
6
Mechanisms of human immunodeficiency virus type 1 concerted integration related to strand transfer inhibition and drug resistance.
Antimicrob Agents Chemother. 2008 Sep;52(9):3358-68. doi: 10.1128/AAC.00271-08. Epub 2008 Jun 30.
10
Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells.
Science. 2000 Jan 28;287(5453):646-50. doi: 10.1126/science.287.5453.646.

引用本文的文献

1
Evidence for Disruption of Mg Pair as a Resistance Mechanism Against HIV-1 Integrase Strand Transfer Inhibitors.
Front Mol Biosci. 2020 Aug 20;7:170. doi: 10.3389/fmolb.2020.00170. eCollection 2020.
2
Mechanistic Studies and Modeling Reveal the Origin of Differential Inhibition of Gag Polymorphic Viruses by HIV-1 Maturation Inhibitors.
PLoS Pathog. 2016 Nov 28;12(11):e1005990. doi: 10.1371/journal.ppat.1005990. eCollection 2016 Nov.
3
Structural Studies of the HIV-1 Integrase Protein: Compound Screening and Characterization of a DNA-Binding Inhibitor.
PLoS One. 2015 Jun 5;10(6):e0128310. doi: 10.1371/journal.pone.0128310. eCollection 2015.
4
Differential effects of the G118R, H51Y, and E138K resistance substitutions in different subtypes of HIV integrase.
J Virol. 2015 Mar;89(6):3163-75. doi: 10.1128/JVI.03353-14. Epub 2014 Dec 31.
5
Pharmacokinetics and dose-range finding toxicity of a novel anti-HIV active integrase inhibitor.
Antiviral Res. 2014 Aug;108:25-9. doi: 10.1016/j.antiviral.2014.05.001. Epub 2014 May 10.
7
Dolutegravir interactions with HIV-1 integrase-DNA: structural rationale for drug resistance and dissociation kinetics.
PLoS One. 2013 Oct 16;8(10):e77448. doi: 10.1371/journal.pone.0077448. eCollection 2013.
8
Inhibiting the HIV integration process: past, present, and the future.
J Med Chem. 2014 Feb 13;57(3):539-66. doi: 10.1021/jm400674a. Epub 2013 Sep 25.
9
HIV Drug Resistance and the Advent of Integrase Inhibitors.
Curr Infect Dis Rep. 2013 Feb;15(1):85-100. doi: 10.1007/s11908-012-0305-1.
10
Novel therapeutic strategies targeting HIV integrase.
BMC Med. 2012 Apr 12;10:34. doi: 10.1186/1741-7015-10-34.

本文引用的文献

4
Kinetic study of the HIV-1 DNA 3'-end processing.
FEBS J. 2006 Mar;273(6):1137-51. doi: 10.1111/j.1742-4658.2006.05139.x.
5
Retroviral DNA integration: reaction pathway and critical intermediates.
EMBO J. 2006 Mar 22;25(6):1295-304. doi: 10.1038/sj.emboj.7601005. Epub 2006 Feb 16.
6
Preliminary mapping of a putative inhibitor-binding pocket for human immunodeficiency virus type 1 integrase inhibitors.
Antimicrob Agents Chemother. 2006 Jan;50(1):134-42. doi: 10.1128/AAC.50.1.134-142.2006.
7
Constructing HIV-1 integrase tetramer and exploring influences of metal ions on forming integrase-DNA complex.
Biochem Biophys Res Commun. 2005 Nov 11;337(1):313-9. doi: 10.1016/j.bbrc.2005.08.274.
8
Integrase inhibitors to treat HIV/AIDS.
Nat Rev Drug Discov. 2005 Mar;4(3):236-48. doi: 10.1038/nrd1660.
9
HIV-1 integrase crosslinked oligomers are active in vitro.
Nucleic Acids Res. 2005 Feb 17;33(3):977-86. doi: 10.1093/nar/gki241. Print 2005.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验